Bio-Light Israeli (BLGTY) 47.1700 $BLGTY BioLight

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bio-Light Israeli (BLGTY) 47.1700 $BLGTY

BioLight Expands Its Product Portfolio With Eye Drops for Dry Eye Syndrome
PR Newswire - Thu May 19, 7:59AM CDT
BioLight Life Sciences Ltd. (TASE: BOLT), ("BioLight" or the "Company", an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today that it has obtained the worldwide rights (excluding Israel and Italy) for the manufacturing, distribution, marketing and sales of a groundbreaking new eye drop product for the treatment of dry eye syndrome (DES) and other ophthalmic indications. The product was in-licensed by BioLight from Fischer Pharmaceuticals Ltd. and RAMOT, the technology transfer arm of the Tel Aviv University. The product has CE Mark marketing approval in Europe, and BioLight is currently evaluating the clinical and regulatory efforts required to commercialize it in other territories around the world.
BOLT: ()

BioLight Reports Positive Second Clinical Study Results for its TeaRx(TM) Multi-Assay Test for Dry Eye Syndrome
PR Newswire - Thu Jan 07, 6:00AM CST
BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the "Company", an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today the completion of a successful U.S. clinical study that was designed to assess the effectiveness of its TeaRx(TM) multi-assay test in evaluating tears' components of healthy subjects as well as of patients suffering from dry eye syndrome ("DES".

BioLight Announces First IOPtiMate(TM) System Sale in Portugal
PR Newswire - Tue Dec 08, 8:23AM CST
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the "Company", a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate(TM) system to a medical center located in Portugal.

BioLight Reports Third Quarter 2015 Financial Results
PR Newswire - Tue Dec 01, 6:00AM CST
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company", a company focused primarily on the discovery, development and commercialization of breakthrough ophthalmic diagnostics and therapeutics, today reported operational and financial results for the third quarter ended September 30, 2015.

BioLight Announces Partnership With Axella Research For CellDetect® Non-Invasive Test for Monitoring Recurrence of Bladder Cancer
PR Newswire - Mon Nov 30, 6:00AM CST
BioLight Life Sciences Investments (OTCQX:BLGTY, TASE:BOLT) ("BioLight" or the "Company", announced today that its cancer diagnostics subsidiary, Micromedic Technologies (TASE:MCTC) ("Micromedic", has entered into a Collaboration Agreement (the "Agreement" with Axella Research LLC ("Axella", to advance the clinical and regulatory efforts required to commercialize the CellDetect® non-invasive diagnostic test for the monitoring of bladder cancer recurrence in the United States.

BioLight Announces Joint Investment in IOPtima Subsidiary
PR Newswire - Wed Nov 25, 6:00AM CST
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company", a company focused primarily on the discovery, development and commercialization of breakthrough ophthalmic diagnostics and therapeutics, announced today that it has entered into a joint financing agreement (the "Agreement" with two Asia-based venture capital firms (the "New Investors", pursuant to which BioLight and the New Investors will make a direct equity investment in BioLight's IOPtima Ltd. subsidiary ("IOPtima" via a private placement. The financing will help IOPtima to continue the global commercialization of its innovative IOPtimate(TM) system used in the treatment of glaucoma, as well as to initiate a regulatory approval pathway process for the IOPtimate(TM) system with the U.S. Food and Drug Administration, commencing 2016.

BioLight's Eye-D Technology to be Featured at the 5th Annual Partnership Opportunities in Drug Delivery Conference in Boston
PR Newswire - Thu Sep 24, 7:17AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company", a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that its Eye-D platform insert will be presented at the 5th Annual Partnership Opportunities in Drug Delivery ("PODD" conference on Monday, October 5, 2015 at 2:00 p.m. Eastern Time at the Boston Intercontinental Hotel in Boston, MA.
PFE: 35.11 (+0.29)

BioLight Reports Second Quarter 2015 Financial Results
PR Newswire - Tue Sep 01, 6:00AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company", a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the second quarter ended June 30, 2015.

BioLight Announces First IOPtiMate(TM) System Sale in Peru
PR Newswire - Thu Aug 13, 8:28AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the "Company", a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate(TM) system to a medical center located in Peru.

BioLight Announces Upcoming Change of ADS Conversion Ratio
PR Newswire - Thu Jul 23, 5:41AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company", a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that, in accordance with recently obtained shareholder approval for a 1-for-10 reverse split of its ordinary shares ("Shares", it will change its American Depositary Share ("ADS" to Share ratio from one (1) ADS representing one hundred (100) Shares to one (1) ADS representing ten (10) Shares, effective August 3, 2015. No action with regard to the ratio change is required from the holders of the ADSs.

BioLight Announces Collaboration With Ora, Inc. for TeaRx(TM) Multi-Parameter Diagnostic Test for Dry Eye Syndrome
PR Newswire - Mon Jun 15, 7:58AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE:BOLT) ("BioLight" or the "Company", a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced that it has expanded its relationship with Ora, Inc., a world-leading independent, full-service ophthalmic contract research organization and product development firm, via the signing of a Collaboration Agreement (the "Agreement" pursuant to which the companies will work together to advance the clinical, regulatory and commercial development of BioLight's TeaRx(TM) multi-parameter diagnostic test for dry eye syndrome ("DES".

BioLight Reports First Quarter 2015 Financial Results
PR Newswire - Mon Jun 01, 6:00AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company", a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the first quarter ended March 31, 2015.

BioLight Announces Closing of Upsized US$6.6 Million Private Placement
PR Newswire - Tue May 12, 6:00AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that it has completed an upsized private placement as part of the strategic partnership with Rock-One International Holdings Ltd for aggregate gross proceeds of US$6.6 million.

BioLight Announces First IOPtiMate(TM) System Sale in Hungary
PR Newswire - Mon Apr 13, 6:00AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate(TM) system to a medical center located in Hungary.
BOLT: ()

BioLight Announces First IOPtiMate(TM) System Sale in Poland
PR Newswire - Mon Dec 01, 8:00AM CST
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announces the first sale of an IOPtiMate(TM) system to a medical center located in Poland following a successful product trial.

Merriman Capital Initiates on BioLight Life Sciences Investments Ltd. with a Buy Rating
Thomson Reuters ONE - Thu Oct 30, 8:00AM CDT
SAN FRANCISCO - October 30, 2014 - Merriman Capital, Inc. ("Merriman", a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced that it has initiated equity research coverage of BioLight Life Sciences Investments Ltd. (OTCQX: BLGTY) with a Buy rating and a $12.00 price target.
BOLT: ()

BioLight to Present at the Canaccord Genuity 2014 Medical Technology and Diagnostics Forum
PR Newswire - Wed Oct 22, 9:00AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX:BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that Suzana Nahum-Zilberberg, CEO, and Itai Bar Natan, CFO, will present at the Canaccord Genuity Medical Technology and Diagnostics Forum at the Westin Grand Central in New York, NY.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 37

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 113

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 275

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

Daniel Pink on Leadership and Workplace Evolution Insights

Updated Category News Views 424

Exploring Leadership in a Changing Workplace The recent episode of Info-Tech Research Group's podcast, Digital Disruption, highlights a thought-provoking discussion with bestselling author Daniel Pink, focusing on how leaders can adapt in a time he describes as 'the great sort'. This term encapsulates the ongoing transformation in our approach to work, leadership, and the...

Continue Reading
MORSE Corp's Community Cleanup Initiative: Making an Impact

Updated Category News Views 240

MORSE Corp's Commitment to Community Service MORSE Corp recently dedicated an entire day to community service by hosting a cleanup initiative at local beaches and parks. On a beautiful Wednesday, the organization mobilized its team to gather at a coastal spot to improve the environment and promote community spirit. This initiative is part of their annual effort to...

Continue Reading
FDA's New Proposal to Enhance Nutrition Awareness on Food Labels

Updated Category News Views 125

Revolutionizing Nutrition Transparency for Consumers Today, the U.S. Food and Drug Administration (FDA) is taking significant steps towards improving consumer awareness about the nutritional value of packaged foods. A new proposal dictates that most packaged foods will require a prominent front-of-package (FOP) nutrition label. This initiative is part of a broader...

Continue Reading
CW Bancorp Declares Quarterly Dividend for Shareholders

Updated Category News Views 150

CW Bancorp Announces Dividend Declaration CW BANCORP (OTCQX: CWBK), the parent company of CommerceWest Bank, has approved a quarterly cash dividend. The news comes as the company continues to prioritize shareholder value while supporting its growth journey. Details of the Cash Dividend The Board of Directors of CW Bancorp declared a cash dividend of $0.23 per common...

Continue Reading
Universal Electronics Unveils QuickSet homeSense at CES Event

Updated Category News Views 348

Universal Electronics Introduces QuickSet homeSense Technology Universal Electronics Inc. (NASDAQ: UEIC) has made headlines by launching its innovative QuickSet homeSense technology. This introduction took place at the prestigious International Consumer Electronics Show (CES) where the spotlight is often on groundbreaking tech. UEI, a leader in wireless control solutions,...

Continue Reading